FAL1 Antibody

Mechanisms of Oncogenicity

FAL1 drives cancer progression through two primary pathways:

Cell Cycle Dysregulation:

BMI1 Stabilization:

• FAL1-BMI1 interaction reduces proteasomal degradation of BMI1 .

• Elevated BMI1 increases H2AK119 ubiquitination, silencing tumor suppressors like FAS and FBXW7 .

Experimental Evidence

Preclinical Models:

• RNAi Studies: FAL1 knockdown reduces colony formation by 60–80% in ovarian (A2780) and breast (MDA-MB-231) cancer cell lines .

• Xenografts: Subcutaneous tumors in mice show 70% growth inhibition with FAL1 shRNA treatment .

• Transformation Assays: Ectopic FAL1 expression in human ovarian surface epithelial cells (HOSEs) induces soft agar colony formation .

Clinical Correlations:

Detection and Profiling Techniques

Antibody-Based Methods:

• RNA Immunoprecipitation (RIP): Anti-BMI1 antibodies validate FAL1-BMI1 interaction (p < 0.01 vs. IgG control) .

• Western Blotting: BMI1 antibody confirms FAL1 pulldown specificity in nuclear lysates .

LC-MS Fab Profiling:

• Resolves polyclonal antibody repertoires targeting FAL1-associated antigens, revealing clonal dominance in autoimmune contexts .

Therapeutic Implications

• Biomarker Potential: FAL1 amplification or overexpression may predict resistance to CDK4/6 inhibitors .

• Targeted Therapy: CRISPR/Cas9-mediated FAL1 deletion synergizes with BMI1 inhibitors in preclinical models .